Research programme: monoclonal antibodies - Harbour Biomed/The Wistar Institute
Latest Information Update: 28 Jul 2022
At a glance
- Originator Harbour BioMed; Wistar Institute
- Class Anti-infectives; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for research development in Cancer in China (Parenteral)
- 28 Jul 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Jul 2022 No recent reports of development identified for research development in Infections in China (Parenteral)